ESG401 not checked

Qilu Pharmaceutical

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Main trialPhase 3
“The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.”In the company’s words, NCT06383767 on ClinicalTrials.gov

Other drugs for Metastatic Breast Cancer

All 396 drugs for Metastatic Breast Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jun 2027 A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3Recruiting Jun 2027 A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ESG401

Following is part of Solo: you see every change to ESG401 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in